Year 2019 / Volume 111 / Number 10
Original
The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease

744-749

DOI: 10.17235/reed.2019.5797/2018

Cristina Suárez Ferrer, Marta Abadía Barno, Eduardo Martín Arranz, Andrea Jochems, Laura García Ramírez, Joaquín Poza Cordón, Marta Jaquotot Herranz, Alberto Cerpa Arencibia, María Dolores Martín Arranz,

Abstract
Introduction: simple, reliable and non-invasive biomarkers are needed to enable the early detection of inflammatory activity for the correct management of inflammatory bowel disease (IBD). One of these biomarkers may be serum calprotectin (SC). Material and methods: a prospective study was performed of patients with IBD due to undergo a colonoscopy as part of the common clinical practice. The study parameters included SC, fecal calprotectin (FC) and conventional blood test parameters. Clinical indices (Harvey and Walmsley) and relevant endoscopic scores were completed for each scenario (Simple Endoscopic Score Crohn Disease [SES-CD] and Mayo). Results: fifty-three patients were included in the study, 51% (27 patients) with ulcerative colitis (UC) and 49% (26 patients) with Crohn’s disease (CD). The CS values in UC were significantly higher with an endoscopic Mayo score 2/3 (median score 10.39 mg/ml [IQR: 7.4-12.2]) compared to those with a Mayo score of 0/1 (median 4.07 mg/ml [IQR: 2.9-7.2]) (p = 0.01). The area under the ROC curve (AUCROC) was 0.85 and the sensitivity and specificity were 83.3% and 81.25%, respectively, for a SC cut-off point of 4.4 mg/dl. Furthermore, a higher AUCROC was obtained in comparison with other serological markers for activity (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], hemoglobin [Hb] and platelets). There were no statistically significant differences in the comparison between SC and endoscopic findings in CD (SES CD > 3: 20.1 [IQR: 16.8-23.4] vs SESC ≤ 3:6.25 [IQR: 5.4-7.1]) (p = 0.8). Conclusions: SC is a good indirect marker of inflammatory activity and there was a correlation with endoscopic findings in UC. However, there were no statistically significant differences in the case of CD.
Share Button
New comment
Comments

16/01/2020 19:52:32
INTERESANTE


References
1. Fernando Magro, Paolo Gionchetti, Rami Eliakim et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders .Journal of Crohn's and Colitis, Volume 11, Issue 6, 1 June 2017, Pages 649–670
2. Marcus Harbord, Rami Eliakim, Dominik Bettenwoth et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management . Journal of Crohn's and Colitis, Volume 11, Issue 7, 1 July 2017, Pages 769–784
3. Fernando Gomollon, Axel Dignass, Vito Annese et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management . Journal of Crohn's and Colitis, Volume 11, Issue 1, 1 January 2017, Pages 3–25
4. Paolo Gionchetti, Axel Dignass, Silvio Danese et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations . Journal of Crohn's and Colitis, Volume 11, Issue 2, 1 February 2017, Pages 135–149
5. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55 Suppl 1:1-15.
6. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-5.
7. D'Haens G, Ferrante M, Vermeire S, et al.. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
8. Sipponen T, Savilahti E, Kohlo K, et al.. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.
9. Manolakis AC, Kapsoritakis AN, Tiaka EK, et al.. Calprotectin, calgranulin C, and other members of the S100 protein family in inflammatory bowel disease. Dig Dis Sci. 2011;56:1601–1611.
10. Judd TA, Day AS, Lemberq DA, et al.. Updates of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493–1499.
11. Laharie D, Mesli S, El Hajbi F, et al.. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34:462–469.
12. Molander P, af Björkesten CG, Mustonen H, et al.. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF[alpha] blocking agents. Inflamm Bowel Dis. 2012;18:2011–2017.
13. Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005;54:321-2.
14. Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-9.
15. Nordal HH, Brokstad KA, Solheim M et al .Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017 Jan 12;19(1):3. doi: 10.1186/s13075-016-1201-0.
16. Hurnakova J, Zavada J, Hanova P et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015 Sep 15;17:252. doi: 10.1186/s13075-015-0764-5.
17. Nielsen UB, Bruhn LV, Ellingsen T, Stengaard-Pedersen K, Hornung N .Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate.Scand J Clin Lab Invest 2018 Feb - Apr;78(1-2):62-67. doi: 10.1080/00365513.2017.1413591. Epub 2017 Dec
18. Kopec-Medrek M1, Kucharz EJ Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with anti-TNF therapy. Adv Clin Exp Med. 2018 Mar 13. doi: 10.17219/acem/68362. [Epub ahead of print]
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Suárez Ferrer C, Abadía Barno M, Martín Arranz E, Jochems A, García Ramírez L, Poza Cordón J, et all. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease. 5797/2018


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1327 visits.
This article has been downloaded 637 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 26/06/2018

Accepted: 17/03/2019

Online First: 03/09/2019

Published: 03/10/2019

Article revision time: 258 days

Article Online First time: 434 days

Article editing time: 464 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology